Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 6Lymphoid 2Genitourinary 2Dermatologic 1CNS 1

Conditions

Prostatic Neoplasms 23Neoplasms 2Thromboembolism 1Neoplasm Metastasis 1Genetic Diseases, Inborn 1Castration-resistant Prostate Cancer 1

Interventions

pembrolizumab 28Docetaxel 21Gemcitabine 19Nivolumab 15Paclitaxel 13Prednisone 12Leuprolide 11pazopanib 10Radiotherapy 10Cisplatin 10Sunitinib 9Sorafenib 9Ipilimumab 8Blood Specimen Collection 8Bevacizumab 8avelumab 7atezolizumab 7Therapeutics 7Thalidomide 7Cyclophosphamide 7Carboplatin 7Standard of Care 6Radiation 6Mitomycin 6Interleukin-2 6Cetuximab 6Axitinib 6padeliporfin 5enzalutamide 5cemiplimab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × Ketoconazole × Genitourinary × Clear all
NCT00019695 2024-03-04

Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Terminated
Genitourinary

Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms, Genetic Diseases, Inborn

NCT00298155 2018-08-09

TAPS

University of Washington

Phase 2 Completed
35 enrolled 6 charts
Genitourinary

Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡